Deadlines
   ---------

     *  Abstract Deadline:
       14th January 2011


   Speakers
   --------

   Andrew D. Zelenetz,
   John C. Byrd,
   Sundar Jagannath,
   John P. Leonard,
   Charles Schiffer,
   Tracy Batchelor,
   Jennifer R. Brown,
   Joseph M. Connors,
   Carlo M. Croce,
   Daniel J. DeAngelo,
   Harry Erba,
   Richard I. Fisher,
   Randy D. Gascoyne,
   Steven M. Horwitz,
   Jean-Pierre Issa,
   Ross L. Levine,
   Sagar Lonial,
   Ruben A. Mesa,
   Natarajan Muthusamy,
   Jerald P. Radich,
   Noopur Raje,
   Donna Reece,
   Laurie H. Sehn,
   Sonali M. Smith,
   David Steensma,
   Keith Stewart,
   Martin S. Tallman,
   James C. Wade,
   William G. Wierda,
   Wyndham H. Wilson,
   Anas Younes,
   Jeffrey Zonder

   Overview and Purpose
   The purpose of the 15th Annual International Congress on Hematologic
   Malignancies: Focus on Leukemias, Lymphomas, and Myeloma , a part of
   the PER curriculum on hematologic malignancies, is to provide a unique
   opportunity for physicians to learn from and interact with
   international leaders in order to increase knowledge, apply new data
   to practice, and improve therapy and supportive care for patients with
   leukemia, lymphoma, and myeloma. This annual program is designed to
   facilitate integration of evolving and contemporary standards of care
   for the optimal treatment of patients with hematologic malignancies
   into community oncologists’ practice. To maximize learning, a variety
   of formats will be employed, including “How I Manage� expert
   approaches, multidisciplinary tumor boards, debates, panel
   discussions, and didactic lectures. In addition to reviewing standards
   of care, translational workshops will provide insight into
   next-generation therapeutic strategies.

   Target Audience This educational program is directed toward medical
   oncologists and hematologists interested in the treatment of patients
   with hematologic malignancies. Fellows, nurse practitioners, nurses,
   physician assistants, pharmacists, researchers, and other health care
   professionals interested in the treatment of hematologic malignancies
   are also invited to attend. Learning Objectives At the conclusion of
   this congress, you should be able to: Outline contemporary prognostic
   markers and optimal response-monitoring strategies applicable to
   treating patients with hematologic malignancies Discuss emerging data
   and recent advances in the treatment of patients with newly diagnosed
   hematologic malignancies and integrate key findings into clinical
   practice Compare and contrast the benefits of current and emerging
   hematopoietic stem cell transplantation strategies in leukemia,
   lymphoma, and myeloma and integrate key findings into clinical
   practice Debate the benefits of maintenance therapies in patients with
   leukemia, lymphoma, and myeloma and integrate key findings into
   clinical practice Evaluate the safety and efficacy of recent clinical
   advances in the management of patients with relapsed/refractory
   leukemia, lymphoma, and myeloma and integrate key findings into
   clinical practice Evaluate emerging novel agents for the treatment of
   patients with hematologic malignanci


   4599 Château Blvd., Whistler, British Columbia, V0N 1B4 , Canada

   Loading (May not complete on browsers without Javascript support)...

   Try again